8 Best Serna Bio Alternatives & Competitors (2026)

Recursion applies machine learning to large-scale cellular imaging for phenotypic drug discovery across many targets. Its strength lies in rapid hypothesis generation from millions of experiments, yet it remains primarily cell-phenotype driven rather than RNA-sequence or splicing focused like Serna Bio. Pricing is typically partnership-based; teams seeking explicit RNA modulation may find Recursion broader but less specialized for translation targets.

Insilico uses generative AI and reinforcement learning for de novo molecule design, often starting from protein structures or omics data. Its platform has produced multiple clinical assets, yet it does not center RNA-targeted mechanisms the way Serna Bio does. Best for protein or pathway-level discovery rather than direct splicing modulation.

Exscientia combines generative AI with active learning to design small molecules, mainly against protein targets. It has delivered clinical candidates faster than traditional methods, but lacks Serna Bio's emphasis on RNA biology and unconstrained design for previously undruggable genes. Suitable for structure-enabled programs rather than splicing or translation modulation.

Atomwise applies deep learning to virtual screening of massive compound libraries against protein structures. It offers rapid hit identification for conventional targets, yet lacks Serna Bio's RNA-first paradigm and experimental multiplexed validation for challenging, non-protein mechanisms.

BenevolentAI mines literature and omics with knowledge graphs to identify drug targets and molecules. Its strength is data integration across diseases, but it does not specialize in RNA-targeted small molecules or the synthetic-biology-enabled screening Serna Bio employs for translation and splicing.

Relay integrates computational and experimental methods to drug dynamic proteins. Its motion-based approach improves on static structures, but remains protein-centric and does not replicate Serna Bio's focus on RNA modulation through AI-driven, unconstrained molecular design.

Generate Biomedicines uses generative models to create de novo proteins and antibodies. While powerful for biologics, it diverges sharply from Serna Bio's small-molecule RNA targeting strategy and multiplexed screening platform for intracellular translation and splicing control.